Testosterone replacement therapy (TRT) is a class of hormone replacement therapy in which androgens, often testosterone, are replaced. Testosterone replacement therapy (TRT) is an FDA-approved medical treatment for men of any age who have low testosterone, a hormone necessary for male sexual development.
Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.
The global average price of testosterone replacement therapy is in the decreasing trend, from 45.4 USD/Unit in 2012 to 34.9 USD/Unit in 2016. With the situation of global economy, prices will be in decreasing trend in the following five years.
The classification of testosterone replacement therapy includes gels, injections, patches and other types, and the proportion of gels in 2016 is about 72%.
Testosterone replacement therapy is widely sold in hospitals, clinics and other field. The most proportion of testosterone replacement therapy is sold in clinics, and the consumption proportion is about 43%.
North America region is the largest supplier of testosterone replacement therapy, with a production market share nearly 86% in 2016. Europe is the second largest supplier of Testosterone Replacement Therapy, enjoying production market share nearly 9.9% in 2016.
North America is the largest consumption place, with a consumption market share nearly 83% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 12%.
Market competition is intense. AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan)
Bayer, etc. are the leaders of the industry. The top five players together held about 80% of the market in the same year and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
The global Testosterone Replacement Therapy market is valued at 1820 million US$ in 2018 is expected to reach 1300 million US$ by the end of 2025, growing at a CAGR of -4.1% during 2019-2025.
This report focuses on Testosterone Replacement Therapy volume and value at global level, regional level and company level. From a global perspective, this report represents overall Testosterone Replacement Therapy market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
AbbVie
Endo International
Eli lilly
Pfizer
Actavis (Allergan)
Bayer
Novartis
Teva
Mylan
Upsher-Smith
Ferring Pharmaceuticals
Kyowa Kirin
Acerus Pharmaceuticals
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Gels
Injections
Patches
Other
Segment by Application
Hospitals
Clinics
Others
Summary:
Get latest Market Research Reports on Testosterone Replacement Therapy . Industry analysis & Market Report on Testosterone Replacement Therapy is a syndicated market report, published as Global Testosterone Replacement Therapy Market Research Report 2019. It is complete Research Study and Industry Analysis of Testosterone Replacement Therapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.